<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25275585</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator.</ArticleTitle><Pagination><StartPage>e1004422</StartPage><MedlinePgn>e1004422</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1004422</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1004422</ELocationID><Abstract><AbstractText>Viruses utilize host factors for their efficient proliferation. By evaluating the inhibitory effects of compounds in our library, we identified inhibitors of cyclophilin A (CypA), a known immunosuppressor with peptidyl-prolyl cis-trans isomerase activity, can significantly attenuate EV71 proliferation. We demonstrated that CypA played an essential role in EV71 entry and that the RNA interference-mediated reduction of endogenous CypA expression led to decreased EV71 multiplication. We further revealed that CypA directly interacted with and modified the conformation of H-I loop of the VP1 protein in EV71 capsid, and thus regulated the uncoating process of EV71 entry step in a pH-dependent manner. Our results aid in the understanding of how host factors influence EV71 life cycle and provide new potential targets for developing antiviral agents against EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qing</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tsinghua-Peking Center for Life Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry &amp; Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing, China; School of Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuna</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiaoyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Wenzhong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Pharmacy, East China University of Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinglan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Beijing No. 4 High School, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Pharmacy, East China University of Science and Technology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Zihe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Tsinghua-Peking Center for Life Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry &amp; Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Zhiyong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China; Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D021984">Cyclophilin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021984" MajorTopicYN="N">Cyclophilin A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25275585</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-13-03304</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Mei Q, Li J, He H (2012) Cyclophilin A and viral infections. Biochem Biophys Res Commun 424: 647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092870</ArticleId><ArticleId IdType="pubmed">22814107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienkowska-Haba M, Patel HD, Sapp M (2009) Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5: e1000524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709439</ArticleId><ArticleId IdType="pubmed">19629175</ArticleId></ArticleIdList></Reference><Reference><Citation>Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, et al. (1994) Functional association of cyclophilin A with HIV-1 virions. Nature 372: 363&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969495</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke EK, Yuan HE, Luban J (1994) Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372: 359&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, et al. (2003) Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism. J Biol Chem 278: 43188&#x2013;43201.</Citation><ArticleIdList><ArticleId IdType="pubmed">12881523</ArticleId></ArticleIdList></Reference><Reference><Citation>Colgan J, Yuan HE, Franke EK, Luban J (1996) Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J Virol 70: 4299&#x2013;4310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190362</ArticleId><ArticleId IdType="pubmed">8676452</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushkarsky T, Zybarth G, Dubrovsky L, Yurchenko V, Tang H, et al. (2001) CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proceedings of the National Academy of Sciences of the United States of America 98: 6360&#x2013;6365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33473</ArticleId><ArticleId IdType="pubmed">11353871</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah VB, Shi J, Hout DR, Oztop I, Krishnan L, et al. (2013) The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol 87: 422&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536424</ArticleId><ArticleId IdType="pubmed">23097435</ArticleId></ArticleIdList></Reference><Reference><Citation>Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, et al. (2005) Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19: 111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15989969</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, et al. (2008) Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 82: 5269&#x2013;5278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395199</ArticleId><ArticleId IdType="pubmed">18385230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, et al. (2009) Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 5: e1000546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718831</ArticleId><ArticleId IdType="pubmed">19680534</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Yang F, Robotham JM, Tang H (2009) Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol 83: 6554&#x2013;6565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698523</ArticleId><ArticleId IdType="pubmed">19386705</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, et al. (2009) Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 50: 1638&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">19821520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanoulle X, Badillo A, Wieruszeski JM, Verdegem D, Landrieu I, et al. (2009) Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem 284: 13589&#x2013;13601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679460</ArticleId><ArticleId IdType="pubmed">19297321</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM (2008) Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 82: 1073&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224455</ArticleId><ArticleId IdType="pubmed">18032500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M (2012) Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. J Virol 86: 9875&#x2013;9887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446629</ArticleId><ArticleId IdType="pubmed">22761365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wang Y, Shan C, Chen C, Xu P, et al. (2012) Enterovirus 71 VPg uridylation uses a two-molecular mechanism of 3D polymerase. J Virol 86: 13662&#x2013;13671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503026</ArticleId><ArticleId IdType="pubmed">23055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou Z, Sun Y, Rao Z (2013) Current progress in antiviral strategies. Trends in Pharmacological Sciences 35: 86&#x2013;102 10.1016/j.tips.2013.1011.1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112804</ArticleId><ArticleId IdType="pubmed">24439476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wang Y, Shan C, Sun Y, Xu P, et al. (2013) Crystal Structure of Enterovirus 71 RNA-Dependent RNA Polymerase Complexed with Its Protein Primer VPg: Implication for a trans Mechanism of VPg Uridylylation. J Virol 87: 5755&#x2013;5768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648134</ArticleId><ArticleId IdType="pubmed">23487447</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, et al. (2012) Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 287: 6406&#x2013;6420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ (2010) Picornaviruses. Current topics in microbiology and immunology 343: 43&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018333</ArticleId><ArticleId IdType="pubmed">20397067</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, et al. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15: 794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15: 798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Neculai D, Schwake M, Ravichandran M, Zunke F, Collins RF, et al... (2013) Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature.</Citation><ArticleIdList><ArticleId IdType="pubmed">24162852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF (2013) Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87: 611&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, Ho MS (2011) Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 85: 11809&#x2013;11820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni S, Yuan Y, Huang J, Mao X, Lv M, et al. (2009) Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J Med Chem 52: 5295&#x2013;5298.</Citation><ArticleIdList><ArticleId IdType="pubmed">19691347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Sun Y, Guo Y, Lou Z (2013) Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses. Trends Microbiol 21: 475&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">23953596</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Sun L, Yu M, Wang Z, Xu C, et al. (2009) Cyclophilin A interacts with influenza A virus M1 protein and impairs the early stage of the viral replication. Cell Microbiol 11: 730&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">19207730</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhao Z, Xu C, Sun L, Chen J, et al. (2012) Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein. PLoS One 7: e31063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275614</ArticleId><ArticleId IdType="pubmed">22347431</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG (2012) Crystal structure of human enterovirus 71. Science 336: 1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zydowsky LD, Etzkorn FA, Chang HY, Ferguson SB, Stolz LA, et al. (1992) Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci 1: 1092&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142182</ArticleId><ArticleId IdType="pubmed">1338979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, et al. (2009) The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 284: 16998&#x2013;17005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719337</ArticleId><ArticleId IdType="pubmed">19380579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, et al. (2012) A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19: 424&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L, Wang X, Spyrou JA, Kelly J, Ren J, et al. (2014) More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol 21: 282&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Lee K, Hafenstein S, Kataoka C, Wakita T, et al. (2013) Enterovirus 71 Binding to PSGL-1 on Leukocytes: VP1-145 Acts as a Molecular Switch to Control Receptor Interaction. PLoS Pathogen 9: e1003511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Cifuente JO, Ashley RE, Conway JF, Makhov AM, et al. (2013) A strain-specific epitope of Enterovirus 71 identified by cryoEM of the complex with Fab from 2 neutralizing antibody. J Virol 87: 11363&#x2013;11370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Huotari J, Helenius A (2011) Endosome maturation. Embo J 30: 3481&#x2013;3500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181477</ArticleId><ArticleId IdType="pubmed">21878991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer J, Schelhaas M, Helenius A (2010) Virus entry by endocytosis. Annu Rev Biochem 79: 803&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">20196649</ArticleId></ArticleIdList></Reference><Reference><Citation>Damsker JM, Bukrinsky MI, Constant SL (2007) Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol 82: 613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846690</ArticleId><ArticleId IdType="pubmed">17540735</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstone DC, Yap MW, Robertson LE, Haire LF, Taylor WR, et al. (2010) Structural and functional analysis of prehistoric lentiviruses uncovers an ancient molecular interface. Cell Host Microbe 8: 248&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">20833376</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Narayanan B, Shah S, Yoder JD, Cifuente JO, et al. (2011) Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor. J Virol 85: 7436&#x2013;7443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126562</ArticleId><ArticleId IdType="pubmed">21561916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, et al. (2013) HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 503: 402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928559</ArticleId><ArticleId IdType="pubmed">24196705</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Kar AK, Sodroski J (2009) Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A. J Virol 83: 10951&#x2013;10962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772774</ArticleId><ArticleId IdType="pubmed">19656870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Wu CN, Shih SR, Ho MS (2002) Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20: 2485&#x2013;2493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12057603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America 102: 9294&#x2013;9299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1166622</ArticleId><ArticleId IdType="pubmed">15939869</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S, Petty TJ, Schibler M, Martinez Y, Gerlach D, et al. (2012) Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog 8: e1002826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX (1989) Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337: 476&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">2492638</ArticleId></ArticleIdList></Reference><Reference><Citation>Galat A, Metcalfe SM (1995) Peptidylproline cis/trans isomerases. Progress in biophysics and molecular biology 63: 67&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">7538221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubner D, Drakenberg T, Forsen S, Fischer G (1991) Peptidyl-prolyl cis-trans isomerase activity as studied by dynamic proton NMR spectroscopy. FEBS Lett 284: 79&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">2060630</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>